NCT06215677Active, not recruitingPhase 2
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
Efficacy of Neoadjuvant Immunotherapy for T4 Deficient Mismatch Repair (dMMR) Colon Cancer: A Prospective, Single-arm, Phase Ⅱ Clinical Trial
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
Due to dMMR colon cancer patients respond poorly to conventional chemotherapy, but immunotherapy can significantly improve the pCR in this group of patients, this study intends to explore whether neoadjuvant immunotherapy can improve the R0 resection rate with preservation of adjacent organs in T4 colon cancer patients with dMMR.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 9 Jan 2024
- Start date
- Jan 2024
- Primary completion date
- May 2025
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Colorectal cancer
- NCT number
- NCT06215677
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 18
- From Jan 2024 to the primary completion date, May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients contraindicated by immunotherapy or surgery;
Other illness
- A history of other malignant tumors (other than cured basal cell carcinoma, cervical carcinoma in situ, surgically treated localized prostate cancer, or surgically resected breast ductal carcinoma in situ) within the past 5 years;
- Complicated with intestinal obstruction, intestinal perforation, gastrointestinal bleeding and other patients requiring emergency surgery; pregnant or lactating women;
- Patients with a history of severe mental illness, immune disease, hormone medication;
Other
- Participated in other clinical researchers in the past 3 months;
- Any other circumstances that the investigator considers inappropriate for inclusion.
Who the study is looking for
- Aged 18-75 years;
- ECOG score 0-2;
- Adenocarcinoma confirmed by pathology and dMMR confirmed by IHC or PCR;
- Tumor located in cecum, ascending colon, transverse colon and sigmoid colon;
- Patients with clinical stage cT4: (1) Loss of space between tumor and adjacent organs or invasion of adjacent organs as assessed by enhanced CT; (2) R0 resection cannot achieve according to intraoperative exploration;
- No evidence of distant metastasis;
- Newly treated patients who have not received treatment including chemotherapy and surgery;
- Liver, kidney and other organs have good function and can tolerate chemotherapy and surgery;
- Patients and family members can understand the study protocol, voluntarily participate in the study and sign informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.